TGTX: TG Therapeutics, Inc.
Performance
TGTX +96.59%
Watchlist
Select an item
Summary
TGTX at a glance
TGTX returned +96.59% over the past year and +12.25% a year over five years. Its worst drop in that year was -21.83%, smaller than 76% of stocks on Redstone, and its Sharpe ratio of 1.61 beats 94% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
44.25%
Actions
Metrics
Risk Indicators
Alpha68.77%
Beta0.62x
Sharpe1.61
Sortino2.72
Omega1.32
Calmar4.43
Martin8.65
Profile
About TGTX
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $9.7B
- Listed
- Dec 1995
- Employees
- 399
- Headquarters
- New York, NY
- Website
- tgtherapeutics.com
Comparisons